QCG
EGRX

Quadrant Capital Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Quadrant Capital Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-88
Closed -$1.71K – 2779
2023
Q2 		$1.71K Sell
88
-1,724
-95% -$40.9K ﹤0.01% 2443
2023
Q1 		$51.4K Buy
1,812
+960
+113% +$28.5K 0.01% 1226
2022
Q4 		$24.9K Buy
852
+250
+42% +$7.95K ﹤0.01% 1549
2022
Q3 		$16K Buy
602
+544
+938% +$20K ﹤0.01% 1674
2022
Q2 		$3K Sell
58
-68
-54% -$3.12K ﹤0.01% 2164
2022
Q1 		$6K Buy
126
+78
+163% +$3.74K ﹤0.01% 1881
2021
Q4 		$2K Buy
48
+4
+9% +$207 ﹤0.01% 2203
2021
Q3 		$2K Buy
44
+26
+144% +$1.28K ﹤0.01% 2212
2021
Q2 		$1K Sell
18
-18
-50% -$743 ﹤0.01% 2351
2021
Q1 		$2K Buy
36
+16
+80% +$743 ﹤0.01% 2134
2020
Q4 		$1K Buy
20
+4
+25% +$187 ﹤0.01% 2227
2020
Q3 		$1K Hold
16
– – ﹤0.01% 2095
2020
Q2 		$1K Hold
16
– – ﹤0.01% 2169
2020
Q1 		$1K Buy
+16
New +$803 ﹤0.01% 2067

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Quadrant Capital Group's EGRX Position: Q3 2023 in Review

Quadrant Capital Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 88 shares — an estimated $1.71K sold.

Quadrant Capital Group first reported a position in EGRX in Q1 2020 and held it in 14 quarters. The position peaked at $51.4K in Q1 2023. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Quadrant Capital Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 88 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.71K.
  • Quadrant Capital Group first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 14 quarters.
  • Quadrant Capital Group's Eagle Pharmaceuticals, Inc. position peaked at $51.4K in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Quadrant Capital Group's 13F filing for Q3 2023, filed 14 Nov 2023.